Metrics as of 10/16/2026, 08:50 AM (Berlin time), refresh in progress.
Gyre Therapeutics Stock
Gyre Therapeutics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Ying Luo
- Employees
- 625
- Market cap
- $679 M
- IPO
- 12/04/2006
Gyre Therapeutics, Inc. is a pharmaceutical company dedicated to discovering, advancing, and bringing to market small-molecule drugs that target inflammation and fibrosis in various organs. The company's key anti-fibrotic medication, ETUARY (Pirfenidone), has received approval for treating idiopathic pulmonary…
Gyre Therapeutics stock: price history
1D
-1.1%
1W
-5.3%
1M
-4.3%
6M
-19.0%
YTD
-9.3%
1Y
-27.8%
2Y
-52.8%
5Y
-89.3%
10Y
-97.3%
Next earnings date
Next earnings date
06/11/2026 (in 20 days)
Volatility around earnings
~5% stronger price swings than usual
Ask the agents about Gyre Therapeutics
Analyst assessment of Gyre Therapeutics
PRICE TARGET LOW
US$16.00
CONSENSUS
US$17.00
MEDIAN
US$17.00
PRICE TARGET HIGH
US$18.00
0
STRONG BUY
1
BUY
0
HOLD
0
SELL
0
STRONG SELL
1
TOTAL · Buy
No current analyst ratings available.
Gyre Therapeutics stock metrics
P/E
-32.18
P/B
4.94
EV/EBITDA
-50.66
RETURN ON EQUITY
-8.1%
NET MARGIN
-36.4%
DEBT/EQUITY
0.03
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
29.5%
FLOAT SHARES
31,252,185
AVG. DAILY VOLUME (30D)
173,986
Insider transactions (SEC)
Ye Weiguo
Ye Weiguo
Ye Weiguo
Ye Weiguo
Ye Weiguo
Institutional holders
Dividends & Stock splits
Dividends
Stock splits
Comparable stocks
Frequently asked questions about Gyre Therapeutics stock
What does Gyre Therapeutics do?
Gyre Therapeutics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Ying Luo, the company employs around 625 people.
The IPO was on 12/04/2006; the stock trades on NASDAQ under the ticker GYRE.
What do analysts say about Gyre Therapeutics stock?
The average price target is US$17.00, ranging from US$16.00 to US$18.00, with a median of US$17.00.
This is an external assessment, not a statement by Market Jury.
When does Gyre Therapeutics report next?
The next earnings date is 06/11/2026.
Around past earnings, price swings were roughly 5% stronger than usual.
Does Gyre Therapeutics pay a dividend?
Yes. The last dividend was US$0.24 per share.
The dividend yield is 0.0% (as of 30/06/2026).
Which stocks are comparable to Gyre Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Gyre Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Gyre Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.